Reverse Genetics Schmallenberg Virus Vaccine Plasmid System
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current Schmallenberg virus (SBV) vaccine compositions lack complete genome sequences and are not fully attenuated, posing safety concerns and inefficiencies in inducing strong humoral immune responses.
Innovation Solution
Development of a reverse genetics system using plasmids encoding SBV S, M, and L segments for producing recombinant SBV vaccines, ensuring high safety and efficacy by engineering viruses with reduced virulence and inducing robust immune responses.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If wildtype SBV is used for vaccine production, then strong immune response is achieved, but safety is compromised due to virulence
Solution Approach 1:
The SBV genome is divided into three separate segments (S, M, and L) that are cloned into individual plasmids. This segmentation allows for controlled propagation and engineering of the virus, enabling the creation of attenuated strains through systematic manipulation of each segment while maintaining safety.
Solution Approach 2:
The patent employs reverse genetics to modify viral parameters by introducing mutations in the plasmid-encoded genome segments. These parameter changes result in attenuated virus strains with reduced virulence while preserving immunogenicity, thereby improving safety without sacrificing vaccine efficacy.
2Reliability
If reverse genetics system is used to engineer attenuated virus, then safety is improved, but manufacturing complexity increases
Solution Approach 1:
The reverse genetics system divides the viral genome into discrete plasmid segments, each encoding a specific genome segment. This segmentation simplifies the manufacturing process by allowing independent cloning, propagation, and quality control of each segment before assembly, thereby reducing overall manufacturing complexity despite the sophisticated approach.
Solution Approach 2:
The reverse genetics system developed in this patent creates a universal platform that can be used to produce multiple attenuated SBV strains and potentially other bunyaviruses. The standardized plasmid constructs and transfection protocols establish a multi-functional system that reduces complexity by providing a reusable framework for vaccine production.
3Manufacturing precision
If complete genome sequence is obtained, then vaccine efficacy is improved, but sequencing and assembly difficulty increases
Solution Approach 1:
The complete SBV genome was obtained by sequencing and assembling the three separate plasmid-encoded segments (S, M, and L). This segmentation approach simplified the sequencing process by breaking down the complex viral genome into manageable pieces that could be individually sequenced and then accurately reassembled, thereby improving manufacturing precision without overwhelming sequencing difficulty.
Solution Approach 2:
The patent creates accurate copies of the complete SBV genome through plasmid-based cloning. These copied sequences serve as reference standards for vaccine production and quality control, enabling precise manufacturing while avoiding the need to repeatedly perform difficult sequencing operations. The cloned plasmids act as stable, reproducible templates.
Data Source
AI summary
The present invention relates to compositions comprising replication defective Schmallenberg virus vaccines, methods of producing the vaccines, and the administration of such vaccines to animals, including ovines and bovines. The invention further relates to methods for providing long-term protective immunity against Schmallenberg in animals, including ovines and bovines.